United States: Investing In Cuban Health Care Biotech Industries

The Obama Administration made significant new regulatory changes to allow certain investment opportunities in the Cuban health care and biotech industries. While many barriers remain, US firms in the health care industry can now begin investing in the Cuban market. Many companies, hospitals and universities are already seeking strategic relationships with Cuban drug producers, medical service providers and biotech firms to create research and business opportunities.

The United States government is encouraging US companies to seek opportunities in Cuba within the legal limitations still imposed and the Cuban government is cautiously welcoming foreign investment in the health care and biotech industries. US companies interested in exploring these opportunities must understand the parameters of relevant US laws and regulations, Cuban foreign investment law and the economic environment on the island.

Compliance with US Laws and Regulations

Cuban Sanctions Regulations and Export Controls Regulations

The Obama Administration has issued new and amended regulations that have significantly relaxed the broad prohibitions and restrictions on US trade with, and investment in, Cuba. However, the trade embargo is still in place and will remain so until the US Congress amends or repeals certain laws. The US government continues to prohibit exporting to Cuba, importing from Cuba, investing in Cuba, and engaging in transactions involving property in which Cuba or a Cuban national has an interest without either a general or specific license from the US Department of Treasury's Office of Foreign Asset Control (OFAC).

The regulatory and policy initiatives of OFAC and the US Department of Commerce's Bureau of Industry and Security (BIS) have eased certain restrictions that apply to travel, trade and financial dealings with Cuba. Under a series of new general licenses (e.g., requiring no application or preapproval), OFAC now allows US persons and companies to travel to Cuba for several specified reasons (e.g., professional research and meetings), to export and import certain goods and services, to establish a physical presence for certain business and to make certain investments in Cuba. OFAC also has become more open to considering applications for specific licenses for certain activities and transactions that otherwise remain prohibited. 

Most recently, on October 14, OFAC made additional regulatory changes to allow US persons to engage in joint medical research projects with Cuban nationals. This general license expands the scope of joint research projects to allow both non-commercial and commercial medical research.

OFAC also now authorizes transactions incident to obtaining approval from the US Food and Drug Administration (FDA) of Cuban-origin pharmaceuticals. The general license includes discovery and development, pre-clinical research, clinical research, regulatory review, regulatory approval and licensing, regulatory post-market activities and the importation into the United States of Cuban-origin pharmaceuticals. The regulations also authorize the importation into the United States, and the marketing, sale or other distribution in the United States, of FDA approved Cuban-origin pharmaceuticals.

For several years preceding the recent US-Cuba normalization initiative, BIS has maintained a favorable policy of approving export license applications for exports of medicine and certain medical equipment. BIS also allows for the export and re-export of "items intended to improve the living conditions" of the Cuban people under the new license exception "Support for Cuban People," under which exports of certain medical goods may qualify. Further, BIS now has a case-by-case policy of favorable consideration for exports to Cuba of items for education, food processing, disaster preparedness, relief and response, public health and sanitation, wholesale and retail distribution for domestic consumption by the Cuban people and construction of facilities for treating public water supplies. Other exports that directly benefit the Cuban people or facilitate the Cuban private sector are also viewed favorably.

OFAC also blocks US persons from dealing with certain Cuban persons and entities. For example, US persons may not engage in transactions with certain Cuban military and government officials. The recent liberalization of US policy has not loosened these restrictions. Investors should screen all business transactions against OFAC's lists before moving forward with any deal.

Travel and Engagement

Under OFAC general licenses, US persons may travel to Cuba without preauthorization if they are doing so under any of 12 categories. These categories include several that are relevant to the health care industry: professional research and professional meetings; educational activities; support for the Cuban people; humanitarian projects; and activities of private foundations or research or educational institutes. As a practical matter, trade delegations most regularly travel to Cuba under the "professional research and professional meetings" category. These delegations may engage in preliminary talks with potential partners and, under a new general license, may even enter into contracts that are expressly contingent on obtaining necessary licenses or the future removal of the embargo. Entering into contracts that do not include such contingencies remain prohibited without a specific license.

Investment Opportunities

While Cuba's economy remains a tightly controlled state economy, the Cuban government is looking for strategic partners in certain sectors. Every November, Cuba issues a "Portfolio of Opportunities for Foreign Investment," which advertises various investment opportunities in Cuba being offered by the Cuban government, including opportunities in the health care and biotech sectors. The following is a sampling of the investments offered in the 2016 portfolio:

  • A $90 million investment to build a new industrial biotechnological facility to produce antibodies for therapeutic use in cancer and other chronic non-transmissible diseases;
  • A $70 million investment to build a new biotech facility to produce recombinant proteins for treating cancer and other chronic non-transmissible diseases;
  • An $11 million investment in a sports medicine facility;
  • An $1.5 million investment in a medical tourism center;
  • A plant to manufacture oral biological medicines with the potential for producing anti-salmonella vaccines and cholera probiotics;
  • An $113 million investment to produce 100,000 liters of plasma per year;
  • A $40 million plant to produce solid forms from natural products for the Cuban and Latin American markets;
  • An $120 million investment to produce antibiotics and similar drugs; and
  • Investments in auxiliary services to support the drug industry, including labs, engineering, treatment plants, expendable medical materials and warehousing services.

Cuban Foreign Investment Law

Cuba significantly revised its foreign investment laws in April 2014 to expand investment opportunities and simplify regulations. Under the new law, investment is allowed in all economic sectors, including biotechnology and health care (although not in public health institutions for Cuban citizens). The law also provides for investments in stocks, other securities or bonds that do not fit the definition of direct investment.

After the revisions, investments may now take the form of joint ventures, international economic association agreements, or wholly owned foreign entities, whereas before wholly owned entities were largely prohibited. The Cuban government also reduces taxes for foreign investments. It reduces taxes on profits from 30 percent to 15 percent and eliminates taxes on labor costs entirely.

The Cuban government still controls investment targets and vets all proposals. It will approve a foreign investment with an "authorization" issued, depending on its content and extent, by the Council of State, the Council of Ministers or another authority appointed by the latter. As a practical matter, the Cuban government only approves well-funded foreign investments.


As the title of this article indicates, while much is possible in the Cuban health care and biotech space, investing in Cuba is not easy and restrictions remain under the US embargo. Investing in Cuba requires strict care in complying with relevant US and Cuban laws. Moreover, in Cuba, after decades of isolation, building relationships and trust is critical. Cuba is looking for long-term agreements with trusted partners. Therefore, it is important to start building the relationships long before a deal is signed.

US health care enterprises, including service providers and drug and device developers, have a long history of engaging in the international marketplace. As with many new markets, success requires effective engagement to both develop useful relationships and identify market opportunities. While opportunities remain limited by the embargo, the policy changes of both the US and Cuban governments, together with the Cuban government's regular publication of potential investments, create an opening and opportunity to take the first step in identifying opportunities.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions